Press Releases

May 22, 2015

Nevro Announces First Commercial Procedure of HF10™ Therapy in the United States

Nevro Corp. (NYSE: NVRO) today announced that the first commercial case has been performed in the United States under the company's May 8th, 2015 FDA approval for commercial use of the Senza® spinal cord stimulation (SCS) system, which delivers Nevro's proprietary HF10™ therapy. Read more…

May 18, 2015

Nevro Files S-1 Registration Statement for Proposed Primary and Secondary Public Offering

Nevro Corp. (NYSE: NVRO) today filed a registration statement on Form S-1 with the U.S. Securities and Exchange Commission for a proposed underwritten public offering of its common stock consisting of approximately $75 million of shares to be sold by Nevro and approximately $125 million of shares to be sold by certain of its stockholders. Read more…

May 11, 2015

Nevro Reports First Quarter 2015 Financial Results

Nevro Corp. (NYSE:NVRO) today reported financial results for the three months ended March 31, 2015. Read more…

May 11, 2015

Nevro Announces Filing of Petitions for Inter Partes Review of U.S. Patent No. 8,359,102

Nevro Corp. (NYSE:NVRO) announced that it had learned today that a unit of Boston Scientific Corporation has filed with the U.S. Patent and Trademark Office two petitions for inter partes review challenging the validity of U.S. Patent No. 8,359,102 (the '102 patent). Read more…

May 8, 2015

Nevro Receives FDA Approval for Senza® Spinal Cord Stimulation System Delivering HF10™ Therapy

Nevro Corp. (NYSE: NVRO) today announced that it has received approval from the United States Food and Drug Administration (FDA) for its Senza spinal cord stimulation (SCS) system. Read more…

April 28, 2015

Nevro to Host Conference Call on Monday, May 11, 2015 at 4:30 p.m. ET

Nevro Corp. (NYSE: NVRO) today announced that it will release financial results for the first quarter of 2015 after market close on Monday, May 11, 2015. Read more…

March 18, 2015

Nevro Reports Fourth Quarter and Full Year 2014 Financial Results

Nevro Corp. (NYSE: NVRO) today reported financial results for the three months and full year ended December 31, 2014. Read more…

March 4, 2015

Nevro to Report Operating Results for the Fourth Quarter and Full Year of 2014

Nevro Corp. (NYSE:NVRO) today announced that it will release financial results for the fourth quarter and full year of 2014 after market close on Wednesday, March 18, 2015. Read more…

March 2, 2015

Nevro Appoints Dr. Brad Vale to its Board of Directors

Nevro Corp. (NYSE:NVRO) today announced that Brad Vale, PhD, DVM, former Head of Johnson & Johnson Development Company (JJDC), has been appointed to its Board of Directors, effective March 1, 2015. Read more…

February 4, 2015

Nevro Receives Expanded MR-Conditional Labeling for Senza® Spinal Cord Stimulation System in Europe and Australia

Nevro Corp. (NYSE: NVRO) today announced that it has received CE Mark for expanded MR-conditional labeling. Read more…

January 28, 2015

Nevro to Present at the 2015 Leerink Global Healthcare Conference

Nevro Corp. (NYSE:NVRO) today announced that its management will be presenting at the 2015 Leerink Global Healthcare Conference on Wednesday, February 11th in New York City. Read more…

January 22, 2015

Nevro Receives Approvable Letter from U.S. Food and Drug Administration for Senza® Spinal Cord Stimulation System

Nevro Corp. (NYSE: NVRO) today announced that it has received a letter from the U.S. Food and Drug Administration (FDA) informing the company of the approvability of its Premarket Approval Application (PMA) for the Senza spinal cord stimulation (SCS) system. Read more…

December 29, 2014

Nevro to Present at the J.P. Morgan 33rd Annual Healthcare Conference

Nevro Corp. (NYSE:NVRO) today announced that its management will be presenting at the J.P. Morgan 33rd Annual Healthcare Conference on Monday, January 12th in San Francisco. Read more…

December 15, 2014

Nevro Announces First Draw Down of $20 Million Under Term Loan Facility with CRG

Nevro Corp. (NYSE:NVRO) is announcing that it completed its first draw down under the previously announced term loan facility with CRG LP (formerly known as Capital Royalty) and its affiliate funds (“CRG”) for proceeds of $20 million before closing fees. Read more…

December 2, 2014

Nevro Reports Third Quarter Financial Results

Nevro Corp. (NYSE:NVRO), a medical device company that has developed and commercialized an innovative, evidence-based neuromodulation platform for the treatment of chronic pain, today reported financial results for the three and nine months ended September 30, 2014. Read more…

November 13, 2014

Nevro to Report 2014 Third Quarter Financial Results and Host Conference Call on December 2, 2014

Nevro Corp. (NYSE:NVRO), a medical device company that has developed and commercialized an innovative, evidence-based neuromodulation platform for the treatment of chronic pain, today announced that it will release financial results for the third quarter of 2014 after market close on Tuesday, December 2, 2014. Read more…

November 12, 2014

Nevro Corp. Announces Full Exercise of Over-Allotment Option and Closing of Initial Public Offering

Nevro Corp. (NYSE:NVRO) today announced the closing of its initial public offering of 8,050,000 shares of its common stock at a public offering price of $18.00 per share, which includes the exercise in full by the underwriters of their option to purchase up to 1,050,000 additional shares of common stock to cover over-allotments, if any. Read more…

November 6, 2014

Nevro Corp. Announces Pricing of Initial Public Offering

Nevro Corp. (NYSE:NVRO), a medical device company that has developed and commercialized an innovative, evidence-based neuromodulation platform for the treatment of chronic pain, today announced the pricing of its initial public offering... Read more…

March 31, 2014

Nevro Strengthens Leadership Team with the Appointment of David Caraway, MD, PhD as Chief Medical Officer

Nevro, a growth stage medical device company focused on developing innovative, evidence based solutions in the neuromodulation space, announced today the appointment of Dr. David Caraway as its Chief Medical Officer. Read more…

PATIENT EXPERIENCES

SENZA

Almost 9 of 10 patients preferred Nevro's HF10 therapy over traditional SCS.

Find Out Why »